Canada's Cosciens Biopharma Q3 loss widens on impairment and acquisition costs

OverviewOutlookResult DriversCompany press release:Key DetailsReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automati…